Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Fanale

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Oncogene|August 7, 2021
POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genesLuigi Magrin, Daniele Fanale, Chiara Brando, et al.
Cancer Treatment Reviews|December 7, 2010
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?Sergio Rizzo, Giuseppe Bronte, Daniele Fanale, et al.
Expert Opinion on Biological Therapy|September 12, 2015
Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Francesco Passiglia, Giuseppe Bronte, Marta Castiglia, et al.
Cellular Immunology|February 4, 2018
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?Giuseppe Badalamenti, Daniele Fanale, Lorena Incorvaia, et al.
Oncotarget|April 16, 2016
Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?Daniele Fanale, Valeria Amodeo, Viviana Bazan, et al.
Cancers|March 6, 2021
Type and Gene Location of <i>KIT</i> Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the ExonLorena Incorvaia, Daniele Fanale, Bruno Vincenzi, et al.
Critical Reviews in Oncology/Hematology|November 26, 2015
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinomaFabrizio Bronte, Giuseppe Bronte, Daniele Fanale, et al.
Critical Reviews in Oncology/Hematology|November 9, 2016
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?Giuseppe Bronte, Lorena Incorvaia, Sergio Rizzo, et al.
Oncotarget|July 31, 2016
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathwayDaniela Massihnia, Antonio Galvano, Daniele Fanale, et al.
Journal of Cellular and Molecular Medicine|January 21, 2012
Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cellsLavinia Insalaco, Francesca Di Gaudio, Marianna Terrasi, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Oncogene|August 7, 2021
POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genesLuigi Magrin, Daniele Fanale, Chiara Brando, et al.
Cancer Treatment Reviews|December 7, 2010
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?Sergio Rizzo, Giuseppe Bronte, Daniele Fanale, et al.
Expert Opinion on Biological Therapy|September 12, 2015
Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?Francesco Passiglia, Giuseppe Bronte, Marta Castiglia, et al.
Cellular Immunology|February 4, 2018
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?Giuseppe Badalamenti, Daniele Fanale, Lorena Incorvaia, et al.
Oncotarget|April 16, 2016
Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?Daniele Fanale, Valeria Amodeo, Viviana Bazan, et al.
Cancers|March 6, 2021
Type and Gene Location of <i>KIT</i> Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the ExonLorena Incorvaia, Daniele Fanale, Bruno Vincenzi, et al.
Critical Reviews in Oncology/Hematology|November 26, 2015
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinomaFabrizio Bronte, Giuseppe Bronte, Daniele Fanale, et al.
Critical Reviews in Oncology/Hematology|November 9, 2016
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?Giuseppe Bronte, Lorena Incorvaia, Sergio Rizzo, et al.
Oncotarget|July 31, 2016
Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathwayDaniela Massihnia, Antonio Galvano, Daniele Fanale, et al.
Journal of Cellular and Molecular Medicine|January 21, 2012
Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cellsLavinia Insalaco, Francesca Di Gaudio, Marianna Terrasi, et al.
Pageof 7